BACKGROUND: Therapy with HIV protease inhibitors (PI) has been shown to worsen glucose and lipid metabolism, but whether these changes are caused by direct drug effects, changes in disease status, or body composition is unclear. Therefore, we tested the effects of the PI combination lopinavir and ritonavir on glucose and lipid metabolism in HIV-negative subjects. METHODS: A dose of 400 mg lopinavir/100 mg ritonavir was given twice a day to 10 HIV-negative men. Fasting glucose and insulin, lipid and lipoprotein profiles, oral glucose tolerance, insulin sensitivity by euglycemic hyperinsulinemic clamp, and body composition were determined before and after lopinavir/ritonavir treatment for 4 weeks. RESULTS: On lopinavir/ritonavir, there was an increase in fasting triglyceride (0.89 +/- 0.15 versus 1.63 +/- 0.36 mmol/l; P = 0.007), free fatty acid (FFA; 0.33 +/- 0.04 versus 0.43 +/- 0.06 mmol/l; P = 0.001), and VLDL cholesterol (15.1 +/- 2.6 versus 20 +/- 3.3 mg/dl; P = 0.05) levels. There were no changes in fasting LDL, HDL, IDL, lipoprotein (a), or total cholesterol levels. Fasting glucose, insulin, and insulin-mediated glucose disposal were unchanged, but on a 2 h oral glucose tolerance test glucose and insulin increased. There were no changes in weight, body fat, or abdominal adipose tissue by computed tomography. CONCLUSION: Treatment with 4 weeks of lopinavir/ritonavir in HIV-negative men causes an increase in triglyceride levels, VLDL cholesterol, and FFA levels. Lopinavir/ritonavir leads to a deterioration in glucose tolerance at 2 h, but there is no significant change in insulin-mediated glucose disposal rate by euglycemic hyperinsulinemic clamp.
BACKGROUND: Therapy with HIV protease inhibitors (PI) has been shown to worsen glucose and lipid metabolism, but whether these changes are caused by direct drug effects, changes in disease status, or body composition is unclear. Therefore, we tested the effects of the PI combination lopinavir and ritonavir on glucose and lipid metabolism in HIV-negative subjects. METHODS: A dose of 400 mg lopinavir/100 mg ritonavir was given twice a day to 10 HIV-negative men. Fasting glucose and insulin, lipid and lipoprotein profiles, oral glucose tolerance, insulin sensitivity by euglycemic hyperinsulinemic clamp, and body composition were determined before and after lopinavir/ritonavir treatment for 4 weeks. RESULTS: On lopinavir/ritonavir, there was an increase in fasting triglyceride (0.89 +/- 0.15 versus 1.63 +/- 0.36 mmol/l; P = 0.007), free fatty acid (FFA; 0.33 +/- 0.04 versus 0.43 +/- 0.06 mmol/l; P = 0.001), and VLDL cholesterol (15.1 +/- 2.6 versus 20 +/- 3.3 mg/dl; P = 0.05) levels. There were no changes in fasting LDL, HDL, IDL, lipoprotein (a), or total cholesterol levels. Fasting glucose, insulin, and insulin-mediated glucose disposal were unchanged, but on a 2 h oral glucose tolerance test glucose and insulin increased. There were no changes in weight, body fat, or abdominal adipose tissue by computed tomography. CONCLUSION: Treatment with 4 weeks of lopinavir/ritonavir in HIV-negative men causes an increase in triglyceride levels, VLDL cholesterol, and FFA levels. Lopinavir/ritonavir leads to a deterioration in glucose tolerance at 2 h, but there is no significant change in insulin-mediated glucose disposal rate by euglycemic hyperinsulinemic clamp.
Authors: K Mulligan; C Grunfeld; V W Tai; H Algren; M Pang; D N Chernoff; J C Lo; M Schambelan Journal: J Acquir Immune Defic Syndr Date: 2000-01-01 Impact factor: 3.731
Authors: H K Berthold; K G Parhofer; M M Ritter; M Addo; J C Wasmuth; K Schliefer; U Spengler; J K Rockstroh Journal: J Intern Med Date: 1999-12 Impact factor: 8.989
Authors: Hans J Woerle; Peter R Mariuz; Christian Meyer; Richard C Reichman; Emilia M Popa; Jean M Dostou; Stephen L Welle; John E Gerich Journal: Diabetes Date: 2003-04 Impact factor: 9.461
Authors: Michael P Dubé; Dajun Qian; Hannah Edmondson-Melançon; Fred R Sattler; Diane Goodwin; Carmen Martinez; Vanessa Williams; Debra Johnson; Thomas A Buchanan Journal: Clin Infect Dis Date: 2002-07-23 Impact factor: 9.079
Authors: Sharon Walmsley; Barry Bernstein; Martin King; José Arribas; Gildon Beall; Peter Ruane; Margaret Johnson; David Johnson; Richard Lalonde; Anthony Japour; Scott Brun; Eugene Sun Journal: N Engl J Med Date: 2002-06-27 Impact factor: 91.245
Authors: Shannon G Loelius; Katie L Lannan; Neil Blumberg; Richard P Phipps; Sherry L Spinelli Journal: Thromb Res Date: 2018-07-06 Impact factor: 3.944
Authors: Oliver P Flint; Mustafa A Noor; Paul W Hruz; Phil B Hylemon; Kevin Yarasheski; Donald P Kotler; Rex A Parker; Aouatef Bellamine Journal: Toxicol Pathol Date: 2009-01-26 Impact factor: 1.902
Authors: Phyllis C Tien; Michael F E Schneider; Stephen R Cole; Alexandra M Levine; Mardge Cohen; Jack DeHovitz; Mary Young; Jessica E Justman Journal: J Acquir Immune Defic Syndr Date: 2008-12-01 Impact factor: 3.731